We Lost 20 Years: Fears, Facts, and Current Insights on Menopausal Hormone Therapy (MHT) After the Women’s Health Initiative (WHI) Study

Menopause is a natural process characterized by hormonal changes in women, and the symptoms that arise during this period (such as hot flashes, sleep disturbances, and bone health problems) can significantly affect quality of life. Menopausal Hormone Therapy (MHT) is a frequently used approach to alleviate these symptoms and prevent long-term health complications. Before delving into the evidence-based details of this therapy, it is essential to revisit how misinformation stemming from one study caused the healthcare system to lose two decades and turned hormone therapy into a source of unnecessary fear for millions of women.

The Women’s Health Initiative (WHI) study, published in 2002, raised concerns about the risks of MHT, which were later exaggerated by the media and led to widespread misunderstanding. This article aims to clarify the findings of the WHI study, discuss current scientific data, and present accurate information about the safe and effective use of MHT—helping women make informed, evidence-based decisions rather than fear-driven ones.

What the WHI Study Said — and What We Should Have Understood

The WHI was a large-scale study published in 2002 that examined the effects of MHT on women’s health. The study included women aged 50–79 (average age 63) who generally began hormone therapy 10–12 years after menopause. The primary aim of the study was to evaluate the effects of MHT on cardiovascular disease. However, the types of hormones used and the study’s design limited the generalizability of its results.

In WHI, the hormones used were conjugated equine estrogens (CEE) derived from horse urine and synthetic progestin (medroxyprogesterone acetate, MPA). These differ from the bioidentical hormones commonly used today—such as micronized 17β-estradiol and micronized progesterone. Bioidentical hormones are structurally identical to those naturally produced by the human body and act more physiologically on hormone receptors. Therefore, WHI findings based on older hormone formulations cannot be directly applied to current clinical practice.

Key Findings of the WHI Study

The WHI evaluated MHT in two main groups: combined estrogen + progesterone therapy and estrogen-only therapy.

Combined Therapy (Estrogen + Progestin)

• A slight increase in breast cancer risk was observed (approximately 8 additional cases per 10,000 women per year). However, this risk was lower in women who began therapy at a younger age (50–59 years) and within the early postmenopausal phase.
• A mild reduction in colon cancer risk was noted.
• For cardiovascular disease, an increased risk was observed when therapy was initiated after age 60, but neutral or mildly protective effects were found in women aged 50–59.

Estrogen-Only Therapy

• No increase in breast cancer risk was observed; in some studies, a slight reduction was even reported.
• Neutral or protective effects on cardiovascular health were documented, particularly when therapy was started early in menopause.

Long-Term Data and Updated Findings

Follow-up analyses from the WHI and subsequent studies have revealed a more positive picture regarding the safety and efficacy of MHT:

• Overall Mortality: When started early, MHT may reduce the risk of death from all causes.
• Bone Health: MHT significantly reduces the risk of osteoporosis and fractures, thereby improving quality of life in older age.
• Brain Health: Women aged 50–59 who began therapy showed a reduction in mortality from neurodegenerative diseases such as Alzheimer’s. However, starting therapy after age 65 may slightly increase the risk of dementia, making the timing of initiation critical.
• Quality of Life: MHT effectively alleviates menopausal symptoms—such as hot flashes, night sweats, sleep disturbances, and vaginal dryness—improving overall well-being.

Misinterpretation of WHI Results

The WHI results were amplified and taken out of context by the media. Headlines such as “Hormone therapy causes breast cancer and heart disease” created unnecessary fear, leading millions of women to avoid MHT. Consequently, the incidence of osteoporosis, fractures, cardiovascular disease, and even early mortality increased. However, modern data confirm that MHT is safe when used appropriately in the right patient population. Specifically:

• When initiated early (ages 50–59 or within 10 years of menopause), MHT shows neutral or even protective effects on cardiovascular disease and overall mortality.
• Bioidentical hormones offer a safer and more physiological profile compared to older formulations.

How to Use MHT Safely

The decision to start MHT should be individualized based on your specific health needs. Your physician will consider the following factors to create a personalized treatment plan:

• Age and Timing: Early initiation lowers risks and enhances benefits.
• Health Status: Factors such as smoking, obesity, and family history of breast cancer or heart disease must be evaluated.
• Hormone Type: Bioidentical hormones (micronized 17β-estradiol and micronized progesterone) are preferred today for their safety and natural receptor affinity.
• Dose and Duration: The lowest effective dose for the shortest duration is recommended to minimize risks.

Conclusion: Informed Choices in the Light of Real Science

When used correctly and for the appropriate patient group, Menopausal Hormone Therapy (MHT) not only relieves symptoms but also offers long-term health benefits. While the WHI study provided valuable data, its limitations and misinterpretations created unnecessary fear. Today’s medical understanding—supported by bioidentical hormones and individualized treatment approaches—allows for much safer therapeutic strategies.

If you have concerns, discuss the risks and benefits openly with your physician. Based on scientific evidence, a treatment plan tailored to your age, health status, and needs can help you navigate menopause in a healthier, more comfortable way. Do not let outdated fears guide your choices—make informed decisions in partnership with your healthcare provider.

1. Menopausal Hormone Therapy (MHT): Definition and Purpose

Hormone Therapy in Menopause: Clinical Overview

Menopausal Hormone Therapy (MHT), commonly referred to as “hormone replacement therapy (HRT)” by the public, is a clinical term used specifically for women during menopause or the perimenopausal transition. Its goal is to alleviate symptoms caused by systemic estrogen deficiency due to decreased ovarian function and to reduce long-term health risks.

In women under 45 with premature menopause or primary ovarian insufficiency, the term “hormone replacement therapy” may be more appropriate. The concept of MHT generally applies to women over 45 experiencing the natural menopausal transition.

Primary Indications:

• Moderate to severe vasomotor symptoms (e.g., hot flashes, night sweats)
• Genitourinary Syndrome of Menopause (GSM): Vaginal dryness, pain during intercourse (dyspareunia), and urinary symptoms

Additional Benefits:

MHT prevents bone loss and reduces the risk of osteoporotic fractures. However, the U.S. Preventive Services Task Force (USPSTF) does not recommend initiating hormone therapy solely for osteoporosis prevention.

Pathophysiology

Menopause occurs when ovarian function ceases, leading to systemic estrogen deficiency. This hormonal shift causes:

• Vasomotor instability
• Genitourinary atrophy (GSM)
• Accelerated bone loss and increased fracture risk
• Metabolic changes such as insulin resistance, visceral fat accumulation, and dyslipidemia

Composition, Eligibility, and Guideline-Based Use

• Estrogen-only therapy: Used for women who have undergone hysterectomy.
• Estrogen + Progestogen combination: Required for women with an intact uterus to prevent endometrial hyperplasia.
• Local (vaginal) estrogen: Recommended for isolated GSM symptoms to minimize systemic risks.

Eligibility: MHT is recommended for women within 10 years of menopause onset or under age 60, provided they have no contraindications such as:

• History of breast cancer
• Thromboembolic disorders (e.g., DVT, PE)
• Active liver disease

Dose and Duration: Start with the lowest effective dose and reassess periodically to determine ongoing need. MHT is not recommended for the primary or secondary prevention of cardiovascular disease or dementia.

Personalized Approach: Therapy must be tailored to the patient’s age, time since menopause, symptom severity, and comorbid conditions. The benefit–risk balance should consider symptom relief, bone protection, and potential risks like thromboembolism and breast cancer (in combined therapy).

Consistency with International Guidelines

These recommendations align with current guidelines from the International Menopause Society and the Endocrine Society, emphasizing individualized therapy and regular re-evaluation.

2. Hormone Therapy Administration Routes and Dosages

Oral Estrogens (Pills)

Oral estrogens—such as conjugated estrogens or ethinyl estradiol—are widely used in both HRT and contraceptives. When taken orally, they are absorbed through the gastrointestinal system and undergo extensive first-pass metabolism in the liver, affecting both hepatic metabolism and systemic circulation.

Effects on Coagulation Factors

Oral estrogens increase hepatic synthesis of coagulation proteins (factors II, VII, X, fibrinogen, and protein C), which may raise the risk of venous thromboembolism (VTE), particularly deep vein thrombosis (DVT) and pulmonary embolism (PE). Risk depends on dose, age, genetic predisposition (e.g., Factor V Leiden), smoking, obesity, and immobility.

Effects on the Liver

Oral estrogens may cause mild, transient elevations in liver enzymes (ALT, AST, GGT) but rarely result in clinically significant hepatic injury. They also increase HDL cholesterol and reduce LDL, while elevating sex hormone-binding globulin (SHBG). In women without pre-existing liver disease, these effects are usually benign.

However, in those with active hepatitis or cirrhosis, oral forms should be avoided or closely monitored. Transdermal and vaginal estrogen formulations bypass hepatic metabolism and have a more neutral impact on coagulation and liver function—thus preferred for women at high thrombotic or hepatic risk.

Clinical Recommendations

Before starting oral estrogen therapy, the following should be assessed:

• Liver function tests (ALT, AST, GGT, ALP, bilirubin)
• Thromboembolic risk factors (family history, genetic mutations, BMI, lifestyle)

Regular blood monitoring and clinical follow-up are advised throughout treatment.

Transdermal Estrogens (Patches or Gels)

These deliver estrogen through the skin directly into systemic circulation, avoiding the liver’s first-pass effect. They exert less influence on coagulation factors and are preferred for women who smoke, have metabolic disorders, or impaired liver function. They provide stable hormone levels and reduce side effects.

Vaginal Estrogens (Creams/Rings)

Used primarily for localized symptoms such as vaginal dryness or pain during intercourse. They have minimal systemic absorption and are effective for Genitourinary Syndrome of Menopause (GSM), including in women with a history of breast cancer under supervision.

Progesterone Use

Women with a uterus must receive progesterone alongside estrogen to prevent endometrial thickening and cancer risk. Commonly used forms include:

• Micronized progesterone (bioidentical, closest to natural form)
• Medroxyprogesterone acetate, norethindrone acetate, and drospirenone

Dosing is customized based on symptom severity, risk profile, and estrogen dosage.

Androgen Hormones

Levels of testosterone and DHEA decline during menopause, often leading to reduced libido and fatigue. In selected women with hypoactive sexual desire disorder (HSDD), testosterone therapy may be considered. Female dosing is typically one-tenth of male levels, with monitoring of total testosterone, free testosterone, and DHEAS. For localized vestibular pain, DHEA creams—which convert to both estrogen and androgen—can be an effective option.

3. Non-Hormonal Alternatives and the Importance of Lifestyle Modification

For women who cannot or choose not to undergo hormone therapy, several non-hormonal alternatives are available:

• SSRIs/SNRIs (e.g., paroxetine, venlafaxine) can reduce hot flashes.
• Gabapentin—commonly used for nerve pain—can ease night sweats and hot flashes.
• Clonidine helps regulate vasodilation and reduce hot flash intensity.
• Phytotherapy—such as black cohosh, soy isoflavones, and red clover—may offer relief for some women but should always be used under medical supervision.

Lifestyle Adjustments

• Mediterranean diet
• At least 150 minutes of exercise per week
• Sleep hygiene
• Avoidance of smoking and alcohol
• Stress management

These lifestyle modifications play a major role in alleviating menopausal symptoms and promoting long-term health.